Cosmo Pharmaceuticals N.V.'s Aries Pharmaceuticals, Inc. said early Monday that its Aemcolo medication has been approved in the U.S. for traveler's diarrhea, making it the first antibiotic approved for the condition in more than a decade, according to the company. The product, a formulation of the antibiotic rifamycin that is delivered to the colon for traveler's diarrhea caused by E. coli, will be available in pharmacies in the first quarter of next year. You can probably guess what the symptoms of traveler's diarrhea are; the condition isn't usually serious when it happens to healthy adults but "can certainly make for an unpleasant trip," according to the Centers for Disease Control and Prevention. Cosmo Pharmaceuticals shares were up 4% on Monday; shares have dropped nearly 6% over the last three months, compared with a 4% drop in the S&P 500 and a 1% decline in the Dow Jones Industrial Average .
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJ - 🏆 98. / 63 Read more »
Source: WSJ - 🏆 98. / 63 Read more »
Source: NBCNews - 🏆 10. / 86 Read more »
Source: USATODAY - 🏆 100. / 63 Read more »